BioStem Technologies Selects KPMG as Its Independent Auditor
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 27 2025
0mins
Should l Buy CBZ?
Source: Yahoo Finance
New Audit Firm Appointment: BioStem Technologies has appointed KPMG LLP as its new independent registered public accounting firm, replacing Marcum LLP, effective October 22, 2025, to support its growth and capital markets strategy.
Uplisting to Nasdaq: The company plans to proceed with its uplisting to the Nasdaq Capital Market following the completion of its audits for the fiscal years 2024 and 2025, aiming to enhance visibility, stock liquidity, and market valuation.
Company Overview: BioStem Technologies specializes in developing and commercializing placental-derived products for advanced wound care, utilizing its proprietary BioREtain® processing method to maintain growth factors and tissue structure.
Quality Assurance: The company’s quality management system has been accredited by the American Association of Tissue Banks, ensuring compliance with Good Tissue Practices and Good Manufacturing Processes at its FDA registered facility in Pompano Beach, Florida.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CBZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CBZ
Wall Street analysts forecast CBZ stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 27.010
Low
60.00
Averages
60.00
High
60.00
Current: 27.010
Low
60.00
Averages
60.00
High
60.00
About CBZ
CBIZ, Inc. is a professional services advisor to middle-market businesses and organizations nationwide. It provides a range of accounting, tax, advisory, benefits, insurance, and technology services. It delivers its services through three groups: Financial Services, Benefits and Insurance Services, and National Practices. Financial Services is comprised of traditional accounting services, tax return preparation, administrative services, financial and risk advisory, consulting, valuation, and IT services. Benefits and Insurance Services provides brokerage and consulting along lines of service which include group health benefits consulting and brokerage, property and casualty brokerage, retirement plan advisory, payroll, human capital management, actuarial, life insurance, and other services. National Practices provides managed networking and hardware services consisting of installation, maintenance and repair of computer hardware. It also maintains a cyber risk management program.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Latest Wall Street Rating Updates
- UBS Upgrade: UBS upgrades Adecoagro from Neutral to Buy, raising the price target from $8 to $16.2, indicating the company is poised to benefit from the ongoing Middle East conflict, which is expected to enhance its financial performance.
- HSBC Bullish on Carnival: HSBC upgrades Carnival from Hold to Buy, asserting that the current share price undervalues the resilience of experience-led demand, which is likely to improve the company's market performance in the near future.
- Morgan Stanley Reiterates Meta: Morgan Stanley lowers its price target for Meta from $825 to $775 but maintains it as a top investment idea, suggesting that market sentiment has bottomed out, making it an opportune time to buy.
- Deutsche Bank Upgrades Colgate: Deutsche Bank upgrades Colgate-Palmolive from Hold to Buy, highlighting the company's core business as having long-term investment value and the ability to weather current market volatility effectively.
See More
CBIZ INC: BMO Begins Coverage with Outperform Rating and Sets Target Price at $33
Coverage Rating: The article discusses the coverage rating of BMO, indicating it has been initiated without a performance rating.
Target Price: The target price set for BMO is $33.
See More
CBIZ Director Sells 17,956 Shares Indirectly
- Indirect Sale Details: On March 10, 2026, CBIZ Director Benaree Pratt Wiley indirectly sold 17,956 shares through a trust for approximately $474,000, representing 45.70% of her total pre-transaction holdings, indicating a significant reduction in her stake.
- Holding Structure Analysis: The transaction was entirely trust-based, leaving Wiley's direct holdings unaffected, as she retains 3,336 direct shares and 18,000 indirect shares, suggesting her long-term investment strategy in CBIZ remains intact.
- Market Reaction and Context: With CBIZ shares down over 60% in the past year, this sale could be interpreted as a defensive move; however, the transaction's structure and Wiley's gradual reduction trajectory may exaggerate market reactions.
- Investor Advisory: Before investing in CBIZ, investors should note that The Motley Fool's analyst team has identified other 10 stocks for potential investment, excluding CBIZ, reflecting a cautious outlook on its future performance.
See More
CBIZ Director Sells 17,956 Shares Amid Declining Stock Price
- Director Selling Details: On March 10, 2026, CBIZ Director Benaree Pratt Wiley sold 17,956 shares indirectly for approximately $474,000, representing 45.7% of her total holdings, which is significantly higher than historical medians of 12.2% to 17.42%.
- Holding Structure Analysis: The transaction was conducted entirely through a trust, leaving Wiley's direct holdings unchanged at 3,336 shares, indicating that her direct investment in CBIZ remains unaffected and suggesting that the sale was primarily for trust management purposes.
- Future Holding Outlook: After the sale, Wiley retains 21,336 shares of CBIZ, valued at approximately $560,000, and despite the significant reduction in her holding percentage, her total ownership still represents about 0.04% of the company's outstanding shares.
- Market Reaction and Investor Interpretation: With CBIZ shares down over 60% in the past year, this insider sale could be perceived as a defensive move; however, due to the transaction's structure and Wiley's long-term selling trend, investors should interpret this cautiously and avoid overreacting.
See More
Updated Quant Ratings for Small-Cap Industrial Companies Post Earnings Season
- Top Rated Companies: Innovative Aerosystems (ISSC) achieves a quant rating of 4.98, classified as a Strong Buy, indicating robust performance in profitability and growth, likely attracting increased investor interest.
- Strong Performance: China Yuchai International (CYD) receives a quant rating of 4.84, suggesting enhanced competitiveness in the market, which could drive its stock price up and boost market confidence.
- Low Rating Warning: Terrestrial Energy (IMSR) is rated at 1.03, categorized as a Strong Sell, reflecting weak fundamentals, prompting investors to exercise caution regarding its future performance.
- Market Trends: As the earnings season concludes, investors are focusing on changes in quant ratings, which may influence investment strategies for small-cap stocks, especially amid increasing economic uncertainty.
See More
CBIZ Q4 Earnings Miss Expectations with Revenue Growth
- Disappointing Earnings: CBIZ reported a Q4 Non-GAAP EPS of -$0.70, missing expectations by $0.04, indicating challenges in profitability that could undermine investor confidence.
- Weak Revenue Growth: Revenue increased by 17.9% year-over-year to $542.67 million, yet fell short of expectations by $35.35 million, reflecting intensified market competition and fluctuating customer demand.
- 2026 Financial Outlook: The company projects total revenue for 2026 to be between $2.8 billion and $2.9 billion, showing cautious optimism for growth compared to $2.76 billion in 2025.
- Adjusted Profitability Metrics: Expected adjusted EPS for 2026 is between $3.75 and $3.85, with adjusted EBITDA projected at $450 million to $460 million, although achieving these targets remains a concern.
See More
Latest Wall Street Rating Updates
- UBS Upgrade: UBS upgrades Adecoagro from Neutral to Buy, raising the price target from $8 to $16.2, indicating the company is poised to benefit from the ongoing Middle East conflict, which is expected to enhance its financial performance.
- HSBC Bullish on Carnival: HSBC upgrades Carnival from Hold to Buy, asserting that the current share price undervalues the resilience of experience-led demand, which is likely to improve the company's market performance in the near future.
- Morgan Stanley Reiterates Meta: Morgan Stanley lowers its price target for Meta from $825 to $775 but maintains it as a top investment idea, suggesting that market sentiment has bottomed out, making it an opportune time to buy.
- Deutsche Bank Upgrades Colgate: Deutsche Bank upgrades Colgate-Palmolive from Hold to Buy, highlighting the company's core business as having long-term investment value and the ability to weather current market volatility effectively.
See More
CBIZ INC: BMO Begins Coverage with Outperform Rating and Sets Target Price at $33
Coverage Rating: The article discusses the coverage rating of BMO, indicating it has been initiated without a performance rating.
Target Price: The target price set for BMO is $33.
See More
CBIZ Director Sells 17,956 Shares Indirectly
- Indirect Sale Details: On March 10, 2026, CBIZ Director Benaree Pratt Wiley indirectly sold 17,956 shares through a trust for approximately $474,000, representing 45.70% of her total pre-transaction holdings, indicating a significant reduction in her stake.
- Holding Structure Analysis: The transaction was entirely trust-based, leaving Wiley's direct holdings unaffected, as she retains 3,336 direct shares and 18,000 indirect shares, suggesting her long-term investment strategy in CBIZ remains intact.
- Market Reaction and Context: With CBIZ shares down over 60% in the past year, this sale could be interpreted as a defensive move; however, the transaction's structure and Wiley's gradual reduction trajectory may exaggerate market reactions.
- Investor Advisory: Before investing in CBIZ, investors should note that The Motley Fool's analyst team has identified other 10 stocks for potential investment, excluding CBIZ, reflecting a cautious outlook on its future performance.
See More
CBIZ Director Sells 17,956 Shares Amid Declining Stock Price
- Director Selling Details: On March 10, 2026, CBIZ Director Benaree Pratt Wiley sold 17,956 shares indirectly for approximately $474,000, representing 45.7% of her total holdings, which is significantly higher than historical medians of 12.2% to 17.42%.
- Holding Structure Analysis: The transaction was conducted entirely through a trust, leaving Wiley's direct holdings unchanged at 3,336 shares, indicating that her direct investment in CBIZ remains unaffected and suggesting that the sale was primarily for trust management purposes.
- Future Holding Outlook: After the sale, Wiley retains 21,336 shares of CBIZ, valued at approximately $560,000, and despite the significant reduction in her holding percentage, her total ownership still represents about 0.04% of the company's outstanding shares.
- Market Reaction and Investor Interpretation: With CBIZ shares down over 60% in the past year, this insider sale could be perceived as a defensive move; however, due to the transaction's structure and Wiley's long-term selling trend, investors should interpret this cautiously and avoid overreacting.
See More
Updated Quant Ratings for Small-Cap Industrial Companies Post Earnings Season
- Top Rated Companies: Innovative Aerosystems (ISSC) achieves a quant rating of 4.98, classified as a Strong Buy, indicating robust performance in profitability and growth, likely attracting increased investor interest.
- Strong Performance: China Yuchai International (CYD) receives a quant rating of 4.84, suggesting enhanced competitiveness in the market, which could drive its stock price up and boost market confidence.
- Low Rating Warning: Terrestrial Energy (IMSR) is rated at 1.03, categorized as a Strong Sell, reflecting weak fundamentals, prompting investors to exercise caution regarding its future performance.
- Market Trends: As the earnings season concludes, investors are focusing on changes in quant ratings, which may influence investment strategies for small-cap stocks, especially amid increasing economic uncertainty.
See More
CBIZ Q4 Earnings Miss Expectations with Revenue Growth
- Disappointing Earnings: CBIZ reported a Q4 Non-GAAP EPS of -$0.70, missing expectations by $0.04, indicating challenges in profitability that could undermine investor confidence.
- Weak Revenue Growth: Revenue increased by 17.9% year-over-year to $542.67 million, yet fell short of expectations by $35.35 million, reflecting intensified market competition and fluctuating customer demand.
- 2026 Financial Outlook: The company projects total revenue for 2026 to be between $2.8 billion and $2.9 billion, showing cautious optimism for growth compared to $2.76 billion in 2025.
- Adjusted Profitability Metrics: Expected adjusted EPS for 2026 is between $3.75 and $3.85, with adjusted EBITDA projected at $450 million to $460 million, although achieving these targets remains a concern.
See More
